Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Astronomers have produced the most detailed map yet of dark matter, revealing the invisible framework that shaped the Universe long before stars and galaxies formed. Using powerful new observations ...

OpenJDK project teams will focus work on features such as value types, code reflection, AOT compilation, and structured concurrency in the coming year. Oracle’s Java team in 2026 will work toward ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

Some tech leaders are concerned that the artificial intelligence race will exhaust available land and energy. The solution might lie in orbit. Credit...Soña Lee Supported by By Eli Tan and Ryan Mac ...

The U.S. Senate Banking Committee will not have any markup hearings on market structure legislation defining how federal regulators can oversee the industry until next year, punting on a hoped-for ...

The U.S. Senate negotiations over a crypto market structure bill — the industry's top goal in its policy lobbying — hasn't yet resolved several disagreements as the talks drift toward the holiday ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...